
Sign up to save your podcasts
Or


Send a text
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to consider key takeaways from the Congress. This conversation is organized around adoption of non-invasive testing in clinical development and when drugs will come to market.
After hearing presentations from 43 speakers at the Fourth Global NASH Congress, six SurfingNASH panelists convene once more to debate how long it will take before we have new medicines to use in identifying and treating patients. This is related to the question of when FDA and EMEA will accept non-invasive tests in pivotal trials. There was some disagreement on the year in which events will happen, but not on the basic pattern of market evolution.
By SurfingNASH.com3.9
2424 ratings
Send a text
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to consider key takeaways from the Congress. This conversation is organized around adoption of non-invasive testing in clinical development and when drugs will come to market.
After hearing presentations from 43 speakers at the Fourth Global NASH Congress, six SurfingNASH panelists convene once more to debate how long it will take before we have new medicines to use in identifying and treating patients. This is related to the question of when FDA and EMEA will accept non-invasive tests in pivotal trials. There was some disagreement on the year in which events will happen, but not on the basic pattern of market evolution.

32,245 Listeners

30,716 Listeners

9,758 Listeners

103 Listeners

21,141 Listeners

3,377 Listeners

113,290 Listeners

56,909 Listeners

9,560 Listeners

8,049 Listeners

10,192 Listeners

6,452 Listeners

0 Listeners

420 Listeners

687 Listeners